RNTX — Rein Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Moderna, Netflix, Visa
U.S. STOCKS ON THE MOVE-Rollins Inc, Harley-Davidson, Tesla
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, Tesla
U.S. STOCKS ON THE MOVE-Skechers, Spotify, Twitter
Aileron gains on new early-stage data from chemoprotective drug study
Brief: Aileron Therapeutics Presents Results From Phase 1 Study In Healthy Volunteers Demonstrating Alrn-6924 Induced Cell Cycle Arrest In Bone Marrow Stem Cells And Hair Follicles At Eortc-Nci-Aacr International Conference
Aileron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aileron Therapeutics Reports Q2 2022 Results
Brief: Aileron Therapeutics Inc Says Cash Runway Has Been Extended
Brief: Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer
Brief: Aileron Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Aileron Therapeutics Says Board Appointed Manuel Aivado, Co's CEO To Serve As Co's Principal Financial Officer, Principal Accounting Officer
Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aileron Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Aileron Therapeutics Reports First Quarter 2022 Financial Results
Brief: Aileron Therapeutics - On April 25, 2022, Richard J. Wanstall, CFO, Notified Company Of His Resignation, Effective May 6, 2022
Brief: Aileron Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Highlights
Aileron Therapeutics Inc expected to post a loss of 8cents a share - Earnings Preview
Aileron Therapeutics Inc reports results for the quarter ended in September - Earnings Summary